- Report
- March 2026
- 488 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 372 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 184 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 382 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 360 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 181 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 196 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 174 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 392 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 196 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 293 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 294 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 182 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 262 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- March 2026
- 462 Pages
Global
From €5258EUR$5,850USD£4,565GBP
- Report
- January 2026
- 194 Pages
Global
From €3187EUR$3,545USD£2,766GBP
€3541EUR$3,939USD£3,073GBP
- Report
- January 2026
- 187 Pages
Global
From €3187EUR$3,545USD£2,766GBP
€3541EUR$3,939USD£3,073GBP
- Report
- January 2026
- 182 Pages
Global
From €3187EUR$3,545USD£2,766GBP
€3541EUR$3,939USD£3,073GBP
- Report
- January 2026
- 189 Pages
Global
From €3187EUR$3,545USD£2,766GBP
€3541EUR$3,939USD£3,073GBP
- Report
- January 2026
- 199 Pages
Global
From €3187EUR$3,545USD£2,766GBP
€3541EUR$3,939USD£3,073GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more